Musculoskeletal Pain Market Poised for Transformation During the Forecast Period (2026-2036) as Novel Therapies and Non-Opioid Approaches Reshape Treatment | DelveInsight
The musculoskeletal pain market is poised for steady growth, driven by the rising global burden of osteoarthritis, chronic low back pain, neck pain, and other musculoskeletal disorders. Additionally, the emergence of novel therapeutics and potential disease-modifying therapies such as Rexlemestrocel-L (MPC-06-ID; Mesoblast), TLC599 (Taiwan Liposome Company), Lorecivivint (SM04690; Biosplice), CNTX 0066 (Centrexion Therapeutics), and others is expected to further reshape the treatment landscape and create new growth opportunities over the forecast period.
LAS VEGAS, Aug. 31, 2026 /PRNewswire/ -- Recently published Musculoskeletal Pain Market Insights report includes a comprehensive understanding of current treatment practices, musculoskeletal pain emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].
Musculoskeletal Pain Market Summary
Discover musculoskeletal pain clinical trial 2026 update press release @ https://www.delveinsight.com/report-store/musculoskeletal-pain-market
Key Factors Driving the Growth of the Musculoskeletal Pain Market
Aparna Thakur, Project Manager of Forecasting & Analytics at DelveInsight, said that among emerging therapies, Rexlemestrocel-L is expected to have the highest uptake potential due to its MSC-based regenerative mechanism and ability to address the high unmet need in chronic low back pain. If clinical studies confirm durable pain relief and functional improvement after a single administration, it could emerge as a differentiated, disease-modifying option versus symptomatic therapies.
Musculoskeletal Pain Market Analysis
Musculoskeletal Pain Competitive Landscape
Some of the musculoskeletal pain drugs under development include Rexlemestrocel-L (MPC-06-ID; Mesoblast), TLC599 (Taiwan Liposome Company), Lorecivivint (SM04690; Biosplice), CNTX 0066 (Centrexion Therapeutics), LTG-321 (Latigo Biotherapeutics), PCRX-201 (Pacira BioSciences), PIPE-791 (Contineum Therapeutics), Cebranopadol (Tris Pharma), and others.
Mesoblast's Rexlemestrocel-L is being investigated as a potential treatment for chronic low back pain (CLBP) associated with disc degeneration. The therapy is intended for patients who have exhausted conservative treatment approaches, potentially experienced inadequate responses to epidural steroid injections, and face limited alternatives beyond invasive and expensive surgical procedures. Mesoblast has completed the Phase III clinical development program evaluating rexlemestrocel-L in patients with CLBP.
TLC599 is Taiwan Liposome's proprietary BioSeizer formulation of dexamethasone sodium phosphate (DSP), developed to deliver sustained pain relief for up to 24 weeks. By locally administering a potent and clinically established corticosteroid with a typically short half-life, TLC599 is designed to provide both rapid pain relief and prolonged therapeutic effects. It is described as the first multilamellar and multivesicular lipid-based DSP formulation developed for osteoarthritis, offering a rapid onset of action with sustained drug release for as long as six months. TLC599 has the potential to address approximately 26% of knee osteoarthritis patients in the United States and is currently undergoing Phase III clinical evaluation for the treatment of osteoarthritis.
The anticipated launch of these emerging therapies are poised to transform the musculoskeletal pain market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the musculoskeletal pain market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.
Discover more about the latest treatments for musculoskeletal pain 2026 @ Musculoskeletal Pain Therapeutics Clinical Trials
Recent Developments in the Musculoskeletal Pain Market
Musculoskeletal Pain Epidemiology Segmentation
The musculoskeletal pain epidemiology section provides insights into the historical and current musculoskeletal pain patient pool and forecasted trends for the leading markets. Musculoskeletal Pain is highly prevalent among the general population. In the United States, it affects almost 37% of the population.
The musculoskeletal pain treatment market report proffers epidemiological analysis for the study period 2022–2036 in the leading markets, segmented into:
Musculoskeletal Pain Market Report Metrics
Details
Study Period
2022–2036
Coverage
7MM [The United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].
Musculoskeletal Pain Epidemiology Segmentation
Musculoskeletal Pain Diagnosed Prevalent Cases, Musculoskeletal Pain Gender-specific Diagnosed Prevalent Cases, Musculoskeletal Pain Age-specific Diagnosed Prevalent Cases, and Musculoskeletal Pain Treated Cases
Key Musculoskeletal Pain Companies
Mesoblast, Taiwan Liposome Company, Biosplice, Centrexion Therapeutics, Latigo Biotherapeutics, Pacira BioSciences, Contineum Therapeutics, Tris Pharma, Flexion, Taisho Pharmaceutical, Bioventus, and others
Key Musculoskeletal Pain Therapies
Rexlemestrocel-L (MPC-06-ID), TLC599, Lorecivivint (SM04690), CNTX 0066, LTG-321, PCRX-201, PIPE-791, Cebranopadol, Zilretta/FX006, LOQOA TAPE, DUROLANE, and others
Scope of the Musculoskeletal Pain Market Report
Download the report to understand the musculoskeletal pain treatment market @ Musculoskeletal Pain Drugs
Table of Contents
1
Musculoskeletal Pain Market Key Insights
2
Musculoskeletal Pain Market Report Introduction
3
Executive Summary of Musculoskeletal Pain
4
Key Events
5
Epidemiology and Market Forecast Methodology of Musculoskeletal Pain
6
Musculoskeletal Pain Market Overview at a Glance
6.1
Market Share (%) Distribution of Musculoskeletal Pain in 2025
6.2
Market Share (%) Distribution of Musculoskeletal Pain in 2036
7
Disease Background and Overview of Musculoskeletal Pain
7.1
Introduction
7.2
Types of Musculoskeletal Pain
7.3
Signs and Symptoms of Musculoskeletal Pain
7.4
Causes of Musculoskeletal Pain
7.5
Pathophysiology of Musculoskeletal Pain
7.6
Diagnosis of Musculoskeletal Pain
7.7
Biomarkers for Musculoskeletal Pain
8
Treatment of Musculoskeletal Pain
9
Epidemiology and Patient Population of Musculoskeletal Pain
9.1
Key Findings
9.2
Assumptions and Rationale: The 7MM
9.3
The United States
9.3.1
Musculoskeletal Pain Diagnosed Prevalent Cases in the United States
9.3.2
Musculoskeletal Pain Age-specific Cases in the United States
9.3.3
Musculoskeletal Pain Gender-specific Cases in the United States
9.3.4
Musculoskeletal Pain Total Treated Cases in the United States
9.4
EU4 and the UK
9.5
Japan
10
Patient Journey of Musculoskeletal Pain
11
Marketed Therapies of Musculoskeletal Pain
11.1
Marketed Competitive Landscape of Musculoskeletal Pain
11.2
ZILRETTA: Flexion Therapeutics
11.2.1
Product Description
11.2.2
Regulatory Milestones
11.2.3
Other Development Activities
11.2.4
Summary of Pivotal Trials
11.2.5
Analyst's Views
11.3
LOQOA TAPE: Taisho Pharmaceutical
List to be continued in report…
12
Emerging Therapies of Musculoskeletal Pain
12.1
Emerging Competitive Landscape of Musculoskeletal Pain
12.2
Rexlemestrocel-L (MPC-06-ID): Mesoblast
12.2.1
Product Description
12.2.2
Other Developmental Activities
12.2.3
Clinical Development
12.2.4
Safety and Efficacy
12.2.5
Analyst's Views
12.3
TLC599: Taiwan Liposome Company
List to be continued in the report…
13
Musculoskeletal Pain Market: 7MM Analysis
13.1
Key Findings
13.2
Musculoskeletal Pain Market Outlook
13.3
Conjoint Analysis
13.4
Key Musculoskeletal Pain Market Forecast Assumptions
13.5
Total Market Size of Musculoskeletal Pain in the 7MM
13.6
The United States Musculoskeletal Pain Market
13.6.1
Total Market Size of Musculoskeletal Pain in the United States
13.6.2
Market Size of Musculoskeletal Pain by Therapies in the United States
13.7
EU4 and the UK Musculoskeletal Pain Market
13.8
Japan Musculoskeletal Pain Market
14
Unmet Needs of Musculoskeletal Pain
15
SWOT Analysis of Musculoskeletal Pain
16
KOL Views of Musculoskeletal Pain
17
Market Access and Reimbursement
17.1
United States
17.2
EU4 and the UK
17.3
Japan
17.4
Summary and Comparison of Market Access and Pricing Policy Developments in 2025
17.5
Musculoskeletal Pain: Market Access and Reimbursement
18
Bibliography
19
Musculoskeletal Pain Market Report Methodology
Related Reports
Musculoskeletal Pain Clinical Trial Analysis
Musculoskeletal Pain Pipeline – 2026 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key musculoskeletal pain companies, including Mesoblast, Taiwan Liposome Company, Biosplice, Centrexion Therapeutics, Latigo Biotherapeutics, Pacira BioSciences, Contineum Therapeutics, Tris Pharma, Flexion, Taisho Pharmaceutical, Bioventus, and others.
Degenerative Disc Disease Market
Degenerative Disc Disease Market Insights, Epidemiology, and Market Forecast – 2036 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key degenerative disc disease companies, including Spine Biopharma, DiscGenics, Mesoblast, Grünenthal, AnGes, BioRestorative Therapies, Kolon TissueGene, Citospin, Creative Medical Technology, and others.
Chronic Lower Back Pain Market
Chronic Lower Back Pain Market Insights, Epidemiology, and Market Forecast – 2036 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key CLBP companies including Mesoblast, Eli Lilly and Company, Persica Pharmaceuticals, CHABiotech, Allodynic Therapeutics, Stayble Therapeutics, Xgene Pharmaceutical, Imbrium Therapeutics, Camurus, and others.
Knee Osteoarthritis Market
Knee Osteoarthritis Market Insights, Epidemiology, and Market Forecast – 2036 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key knee osteoarthritis companies including Centrexion Therapeutics, Pfizer, Eli Lilly, Ampio Pharmaceuticals, Galapagos NV, Cytonics, Flexion Therapeutics, and others.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Contact Us
Shruti Thakur
[email protected]
+14699457679
www.delveinsight.com
SOURCE DelveInsight Business Research, LLP